Last $8.75 USD
Change Today 0.00 / 0.00%
Volume 820.0
MRNS On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 11:53 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

marinus pharmaceuticals inc (MRNS) Snapshot

Open
$8.43
Previous Close
$8.75
Day High
$8.75
Day Low
$8.43
52 Week High
09/8/14 - $10.58
52 Week Low
09/22/14 - $5.49
Market Cap
122.6M
Average Volume 10 Days
10.3K
EPS TTM
--
Shares Outstanding
14.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MARINUS PHARMACEUTICALS INC (MRNS)

Related News

No related news articles were found.

marinus pharmaceuticals inc (MRNS) Related Businessweek News

No Related Businessweek News Found

marinus pharmaceuticals inc (MRNS) Details

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.

4 Employees
Last Reported Date: 11/13/14
Founded in 2003

marinus pharmaceuticals inc (MRNS) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $370.9K
Chief Financial Officer, Principal Financial ...
Total Annual Compensation: $30.0K
Chief Clinical Development & Regulatory Offic...
Total Annual Compensation: $359.6K
Compensation as of Fiscal Year 2013.

marinus pharmaceuticals inc (MRNS) Key Developments

Marinus Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM

Marinus Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Christopher Michael Cashman, Executive Chairman, Chief Executive Officer and President.

Marinus Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Marinus Pharmaceuticals, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $2,437,041,000 against $1,321,890,000 a year ago. Net loss applicable to common stockholders was $2,040,711,000 or $0.22 per basic and diluted share against $2,252,776,000 or $4.58 per basic and diluted share a year ago. For the nine months, the company reported loss from operations of $8,365,275,000 against $3,890,091,000 a year ago. Net loss applicable to common stockholders was $9,771,382,000 or $2.79 per basic and diluted share against $6,630,101,000 or $13.50 per basic and diluted share a year ago. Cash used in operating activities was $6.6 million for the nine months ended September 30, 2014 compared to $3.5 million for the same period a year ago.

Marinus Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 01:50 PM

Marinus Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 01:50 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Christopher Michael Cashman, Executive Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRNS:US $8.75 USD 0.00

MRNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.92.35 CHF -1.20
View Industry Companies
 

Industry Analysis

MRNS

Industry Average

Valuation MRNS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARINUS PHARMACEUTICALS INC, please visit www.marinuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.